SlideShare a Scribd company logo
II. Blood and BloodII. Blood and Blood
ComponentsComponents
Terry Kotrla, MS, MT(ASCP)BBTerry Kotrla, MS, MT(ASCP)BB
Spring 2010Spring 2010
Goals Of Blood CollectionGoals Of Blood Collection
 Maintain viability and functionMaintain viability and function
 Prevent physical changesPrevent physical changes
 Minimize bacterial contaminationMinimize bacterial contamination
Anticoagulants Preservative
Solutions
 Anticoagulants prevent blood clottingAnticoagulants prevent blood clotting
 Preservatives provide nutrients for cellsPreservatives provide nutrients for cells
 HeparinHeparin
– Rarely if ever used anymoreRarely if ever used anymore
– Anticoagulant ONLYAnticoagulant ONLY
– Transfuse within 48 hours, preferably 8Transfuse within 48 hours, preferably 8
AnticoagulantsAnticoagulants
CPDCPD CPD-A1CPD-A1
Storage timeStorage time 21 days21 days 35 days35 days
TemperatureTemperature 1-6 C1-6 C 1-6 C1-6 C
Slows glycolytic activitySlows glycolytic activity
AdenineAdenine NoneNone Substrate for ATP synthesisSubstrate for ATP synthesis
VolumeVolume 450 +/- 10%450 +/- 10%
DextroseDextrose Supports ATP generation by glycolyticSupports ATP generation by glycolytic
pathwaypathway
CitrateCitrate Prevents coagulation by binding calciumPrevents coagulation by binding calcium
Additive SolutionAdditive Solution
 Primary bag with satellite bags attached.Primary bag with satellite bags attached.
 One bag has additive solution (AS)One bag has additive solution (AS)
 Unit drawn into CPD anticoagulantUnit drawn into CPD anticoagulant
Additive SolutionAdditive Solution
 Remove platelet rich plasma within 72 hoursRemove platelet rich plasma within 72 hours
 Add additive solution to RBCs, ADSOL, whichAdd additive solution to RBCs, ADSOL, which
consists of:consists of:
– SalineSaline
– AdenineAdenine
– GlucoseGlucose
– MannitolMannitol
 Extends storage to 42 daysExtends storage to 42 days
 Final hematocrit approximately 66%Final hematocrit approximately 66%
Changes Occur During StorageChanges Occur During Storage
 Shelf life = expiration dateShelf life = expiration date
– At end of expiration must have 75% recoveryAt end of expiration must have 75% recovery
– At least 75% of transfused cells remain inAt least 75% of transfused cells remain in
circulation 24 hours AFTER transfusioncirculation 24 hours AFTER transfusion
Storage LesionStorage Lesion
 Biochemical changes which occur at 1-6CBiochemical changes which occur at 1-6C
 Affects oxygen dissociation curve, increasedAffects oxygen dissociation curve, increased
affinity of hemoglobin for oxygen.affinity of hemoglobin for oxygen.
– Low 2,3-DPG, increased OLow 2,3-DPG, increased O22 affinity, less Oaffinity, less O22 released.released.
– pH drops causes 2,3-DPG levels to fallpH drops causes 2,3-DPG levels to fall
– Once transfused RBCs regenerate ATP and 2,3-DPGOnce transfused RBCs regenerate ATP and 2,3-DPG
 Few functional platelets presentFew functional platelets present
 Viable (living) RBCs decreaseViable (living) RBCs decrease
Plasma
hemoglobin
Plasma K+
Viable cells
pH
ATP
2,3-DPG
Plasma Na+
Helps release oxygen
from hemoglobin (once
transfused, ATP & 2,3-
DPG return to normal)
K+Na+
Storage LesionStorage Lesion
 Significant for infants and massiveSignificant for infants and massive
transfusion.transfusion.
 Other biochemical changesOther biochemical changes
– ATP decreasesATP decreases
– Potassium increasesPotassium increases
– Sodium decreasesSodium decreases
– Plasma hemoglobin increasesPlasma hemoglobin increases
Preparation of ComponentsPreparation of Components
 Collect unit within 15 minutes to preventCollect unit within 15 minutes to prevent
activation of coagulation systemactivation of coagulation system
 Draw into closed system – primary bag withDraw into closed system – primary bag with
satellite bags with hermetic seal between.satellite bags with hermetic seal between.
 If hermetic seal broken transfuse within 24 hoursIf hermetic seal broken transfuse within 24 hours
if stored at 1-4C, 4 hours if stored at 20-24Cif stored at 1-4C, 4 hours if stored at 20-24C
Preparation of ComponentsPreparation of Components
 Centrifuge – light spin, platelets suspendedCentrifuge – light spin, platelets suspended
 Remove platelet rich plasma (PRP)Remove platelet rich plasma (PRP)
 Centrifuge PRP heavy spinCentrifuge PRP heavy spin
 Remove platelet poor plasmaRemove platelet poor plasma
 Freeze plasma solid within 8 hoursFreeze plasma solid within 8 hours
 Thaw plasma at 1-4C – precipitate formsThaw plasma at 1-4C – precipitate forms
 Centrifuge, express plasma leavingCentrifuge, express plasma leaving
cryoprecipitate. Store both at -18Ccryoprecipitate. Store both at -18C
 RBCs – CPD – 21 days, ADSOL – 42 days – 1-RBCs – CPD – 21 days, ADSOL – 42 days – 1-
6C6C
Bb unit2 bloodcomponentsspring2010
Preparation of ComponentsPreparation of Components
 Summary – One unit of whole blood canSummary – One unit of whole blood can
produce:produce:
– Packed RBCsPacked RBCs
– Fresh frozen plasma (FFP)Fresh frozen plasma (FFP)
– Cryoprecipitate (CRYO)Cryoprecipitate (CRYO)
– Single donor plasma (SDP) – cyro removedSingle donor plasma (SDP) – cyro removed
– Platelets – terms PC (platelet concentrate) ORPlatelets – terms PC (platelet concentrate) OR
RD PC (random donor platelet concentrate)RD PC (random donor platelet concentrate)
Preparation of ComponentsPreparation of Components
 Sterile docking device joins tubingSterile docking device joins tubing
– Used to add satellite bags to maintain originalUsed to add satellite bags to maintain original
expiration of componentexpiration of component
– May be used to pool componentsMay be used to pool components
Blood Component General InformationBlood Component General Information
 Blood separated into components toBlood separated into components to
specifically treat patients with productspecifically treat patients with product
neededneeded
 Advantages of component separationAdvantages of component separation
– Allow optimum survival of each componentAllow optimum survival of each component
– Transfuse only component neededTransfuse only component needed
Blood Component General InformationBlood Component General Information
 Transfusion practiceTransfusion practice
– Transfusion requires doctor’s prescriptionTransfusion requires doctor’s prescription
– All components MUST be administeredAll components MUST be administered
through a filterthrough a filter
– Infuse quickly, within 4 hoursInfuse quickly, within 4 hours
– D (Rh) neg require D neg cellular productsD (Rh) neg require D neg cellular products
– ABO identical preferred, ABO compatible OKABO identical preferred, ABO compatible OK
– ““Universal donor” – RBCs group O, plasmaUniversal donor” – RBCs group O, plasma
ABAB
Blood Component General InformationBlood Component General Information
 Fresh Whole BloodFresh Whole Blood
– Blood not usually available until 12-24 hoursBlood not usually available until 12-24 hours
– CandidatesCandidates
 Newborns needing exchange transfusionNewborns needing exchange transfusion
 Patients requiring leukoreduced productsPatients requiring leukoreduced products
Blood Component General InformationBlood Component General Information
 Summary of storage temperatures:Summary of storage temperatures:
– Liquid RBCs 1-6CLiquid RBCs 1-6C
– Platelets, Cryo (thawed) and granulocytes 20-Platelets, Cryo (thawed) and granulocytes 20-
24C (room temperature)24C (room temperature)
– ANY frozen plasma product ≤ -18CANY frozen plasma product ≤ -18C
– ANY liquid plasma product EXCEPT Cryo 1-ANY liquid plasma product EXCEPT Cryo 1-
6C6C
Blood ComponentsBlood Components
 CellularCellular
– Red blood cell productsRed blood cell products
– PlateletsPlatelets
– GranulocytesGranulocytes
 PlasmaPlasma
– FFPFFP
– CryoprecipitateCryoprecipitate
Products With Red CellsProducts With Red Cells
Whole BloodWhole Blood
 Clinical indications for use of WB are extremely limited.
 Used for massive transfusion to correct acute
hypovolemia such as in trauma and shock, exchange
transfusion.
 RARELY used today, platelets non-functional, labile
coagulation factors gone.
 Must be ABO identical.
Changes in Stored BloodChanges in Stored Blood
Red Blood Cells, PackedRed Blood Cells, Packed
(PRBC)(PRBC)
 Used to treat symptomatic anemia and routine
blood loss during surgery
 Hematocrit is approximately 80% for non-
additive (CPD), 60% for additive (ADSOL).
 Allow WB to sediment or centrifuge WB, remove
supernatant plasma.
Leukocyte Reduced Red Cells (LR-Leukocyte Reduced Red Cells (LR-
RBC)RBC)
 Leukocytes can induce adverse affects during transfusion, primarily
febrile, non-hemolytic reactions.
 Reactions to cytokines produced by leukocytes in transfused units.
 Other explanations to reactions include: immunization of recipient to
transfused HLA or granulocyte antigens, micro aggregates and
fragmentation of granulocytes.
 Historically, indicated only for patients who had 2 or more febrile
transfusion reactions, now a commonly ordered, popular
component.
 “CMV” safe blood, since CMV lives in WBCs.
 Most blood centers now leukoreduce blood immediately after
collection.
 Bed side filters are available to leukoreduce products during
transfusion.
Leukocyte ReductionLeukocyte Reduction
Washed Red Blood Cells (W-
RBCs)
 Washing removes plasma proteins, platelets, WBCs and
micro aggregates which may cause febrile or urticarial
reactions.
 Patient requiring this product is the IgA deficient patient
with anti-IgA antibodies.
 Prepared by using a machine which washes the cells 3
times with saline to remove and WBCs.
 Two types of labels:
– Washed RBCs - do not need to QC for WBCs.
– Leukocyte Poor WRBCs, QC must be done to guarantee
removal of 85% of WBCs. No longer considered effective
method for leukoreduction.
 e. Expires 24 hours after unit is entered.
Cell Washer to Prepare WashedCell Washer to Prepare Washed
CellsCells
Frozen BloodFrozen Blood
Red Blood Cells Frozen; Red Blood Cells
Deglycerolized (D-RBC)
 Blood is frozen to preserve: rare types, for autologous
transfusion, stock piling blood for military mobilization
and/or civilian natural disasters.
 Blood is drawn into an anticoagulant preservative.
– Plasma is removed and glycerol is added.
– After equilibration unit is centrifuged to remove excess glycerol
and frozen.
 Expiration
– If frozen, 10 years.
– After deglycerolization, 24 hours.
 Storage temperature
– high glycerol -65 C.
– low glycerol -120 C, liquid nitrogen.
Red Blood Cells Frozen; Red Blood Cells
Deglycerolized (D-RBC)
 Thaw unit at 37C, thawed RBCs will have high
concentration of glycerol.
 A solution of glycerol of lesser concentration of the
original glycerol is added.
 This causes glycerol to come out of the red blood cells
slowly to prevent hemolysis of the RBCs.
 After a period of equilibration the unit is spun, the
solution is removed and a solution with a lower glycerol
concentration is added.
 This procedure is repeated until all glycerol is removed,
more steps are required for the high glycerol stored
units.
 The unit is then washed.
Rejuvenated Red Blood Cells
 A special solution is added to expired RBCs up
to 3 days after expiration to restore 2,3-DPG and
ATP levels to prestorage values.
 Rejuvenated RBCs regain normal characteristics
of oxygen transport and delivery and improved
post transfusion survival.
 Expiration is 24 hours or, if frozen, 10 years
Platelet ProductsPlatelet Products
Platelets (PLTS), Platelet Concentrate (PC) or
Random Donor Platelet Concentrate (RD-PC)
 Used to prevent spontaneous bleeding or stop
established bleeding in thrombocytopenic patients.
 Prepared from a single unit of whole blood.
 Due to storage at RT it is the most likely component to
be contaminated with bacteria.
 Therapeutic dose for adults is 6 to 10 units.
 Some patients become "refractory" to platelet therapy.
 Expiration is 5 days as a single unit, 4 hours if pooled.
 Store at 20-24 C (RT) with constant agitation.
 D negative patients should be transfused with D negative
platelets due to the presence of a small number of
RBCs.
Preparation of plateletPreparation of platelet
concentrateconcentrate
RBCs PRP
Plasma
Platelet
concentrate
Platelets (PLTS), Platelet Concentrate (PC) or
Random Donor Platelet Concentrate (RD-PC)
 One bag from ONE donorOne bag from ONE donor
 Need 6-10 for therapeutic doseNeed 6-10 for therapeutic dose
Pooling PlateletsPooling Platelets
 6-10 units transferred into one bag6-10 units transferred into one bag
 Expiration = 4 hoursExpiration = 4 hours
Platelets Pheresis, Apheresis Platelet Concentrate, Single
Donor Platelet Concentrate (SD-PC)
 Used to decrease donor exposure, obtain HLA matched
platelets for patients who are refractory to RD-PC or
prevent platelet refractoriness from occurring.
 Prepared by hemapheresis, stored in two connected
bags to maintain viability.
 One pheresed unit is equivalent to 6-8 RD-PC.
 Store at 20-24 C (RT) with agitation for 5 days, after
combining, 24 hours
 D negative patients should be transfused with D negative
platelets due to the presence of a small number of RBCs
ApheresisApheresis
ApheresisApheresis
Platelets Pheresis
 One bag (unit) fromOne bag (unit) from
one donorone donor
 One unit is aOne unit is a
therapeutic dosetherapeutic dose
 VolumeVolume
approximately 250approximately 250
ccsccs
GranulocytesGranulocytes
Lymphocyte Monocyte
Neutrophils Eosinophils Basophils
Granulocytes
 Primary use is for patients with neutropenia who have
gram negative infections documented by culture, but are
unresponsive to antibiotics.
 Therapeutic efficacy and indications for granulocyte
transfusions are not well defined.
 Better antimicrobial agents and use of granulocyte and
macrophage colony stimulating factors best for adults,
best success with this component has been with babies
 Daily transfusions are necessary.
 Prepared by hemapheresis.
 Expiration time is 24 hours but best to infuse ASAP.
 Store at 20-24 C.
Plasma ComponentsPlasma Components
Fresh Frozen Plasma –Fresh Frozen Plasma –
Volume 200-250ccVolume 200-250cc
Fresh Frozen Plasma
(FFP)
 Used to replace labile and non-labile coagulation
factors in massively bleeding patients OR treat
bleeding associated with clotting factor
deficiencies when factor concentrate is not
available.
 Must be frozen within 8 hours of collection.
 Expiration
– frozen - 1 year stored at <-18 C.
– frozen - 7 years stored at <-65 C.thawed - 24 hours
Fresh Frozen Plasma
(FFP)
 Storage temperature
– frozen -18 C, preferably -30 C or lower
– thawed - 1-6 C
 Thawed in 30-37C water bath or FDA
approved microwave
 Must have mechanism to detect units
which have thawed and refrozen due to
improper storage.
 Must be ABO compatible
Plasma, Liquid Plasma, Recovered
Plasma and Source Plasma
 Used to treat patients with stable clotting factor
deficiencies for which no concentrate is available or for
patients undergoing therapeutic plasmapheresis.
 Prepared by separating the plasma from the RBCs on
or before the 5th day after expiration of the whole
blood.
 Once separated can:
– Freeze, store at -18 C for 5 years
– If not frozen, called liquid plasma, store at 1-6 C for up to 5 days
after expiration of WB.
 Once FFP is one year old can redesignate as Plasma,
expiration is 5 years.
Pooled Plasma/Solvent
Detergent Treated
 Most recently licensed product.
 Prepared from pools of no more than 2500 units of ABO
specific plasma frozen to preserve labile coagulation
factors.
 Treated with chemicals to inactivate lipid-enveloped
viruses.
 Contains labile and non-labile coagulation factors but
lacks largest Von Willebrand’s factor multimers.
 Used same as FFP.Safety concerns
– Decreases disease transmission for diseases tested for.
– Doesn’t inactivate viruses with non-lipid envelopes: parvo virus
B19, hepatitis A, and unrecognized pathogens
Cryoprecipitate (CRYO), Factor VIII
or Anti-Hemophilic Factor (AHF)
 Cold insoluble portion of plasma that precipitates when
FFP is thawed at 1-6C.
 Cryoprecipitate contains high levels of Factor VIII and
Fibrinogen, used for treatment of hemophiliacs and
Von Willebrands when concentrates are not available.
 Used most commonly for patients with DIC or low
fibrinogen levels.
 A therapeutic dose for an adult is 6 to 10 units.
 Can be prepared from WB which is then designated as
"Whole Blood Cryoprecipitate Removed" or from FFP
– Plasma is frozen.
– Plasma is then thawed at 1-6 C, a precipitate forms.
– Plasma is centrifuged, cryoprecipitate will go to
bottom.
– Remove plasma, freeze within 1 hour of preparation
FFP
Frozen
within 8
hours
Thawed
FFP
Cryoprecipitate
(VIII, vW)
Plasma cryoprecipitate, reduced
(TTP, FII, V, Vii, IX, X, XI)
Thaw at 30-37°C
Store at RT 4 hrs
Refrozen with 24 hrs of
separation
Store at ≤18°C 1 yr
5 day expiration at 1-6°C
Cryoprecipitate (CRYO), Factor VIII
or Anti-Hemophilic Factor (AHF)
 Storage Temperature
– Frozen -18 C or lower
– Thawed - room temperature
 Expiration:
– Frozen 1 year
– Thawed 6 hours
– Pooled 4 hours
 Best to be ABO compatible but not
important due to small volume
Cryoprecipitate – volume 15ccsCryoprecipitate – volume 15ccs
Irradiation of Blood Components
Irradiation of Blood Components
 Cellular blood components are irradiated to
destroy viable T- lymphocytes which may cause
Graft Versus Host Disease (GVHD).
 GVHD is a disease that results when
immunocompetent, viable lymphocytes in donor
blood engraft in an immunocompromised host,
recognize the patient tissues as foreign and
produce antibodies against patient tissues,
primarily skin, liver and GI tract. The resulting
disease has serious consequences including
death.
 GVHD may be chronic or acute
Irradiation of Blood Components
 Patients at greatest risk are:
– severely immunosuppressed,
– immunocompromised,
– receive blood donated by relatives, or
– fetuses receiving intrauterine transfusions
 Irradiation inactivates lymphocytes, leaving platelets,
RBCs and granulocytes relatively undamaged.
 Must be labeled "irradiated".
 Expiration date of Red Blood Cell donor unit changes to
28 days.
 May be transfused to "normal" patients if not used by
intended recipient.
Irradiation of Blood Components
Donor Blood Inspection and Disposition
 It is required that donor units be inspected periodically
during storage and prior to issuing to patient.
 The following may indicate an unacceptable unit:
– Red cell mass looks purple or clots are visible.
– Zone of hemolysis observed just above RBC mass, look for
hemolysis in sprigs, especially those closest to the unit.
– Plasma or supernatant plasma appears murky, purple, brown or
red.
– A greenish hue need not cause a unit to be rejected.
– Inspect platelets for aggregates.
 Inspect FFP and CRYO for signs of thawing, evidence of
cracks in bag, or unusual turbidity in CRYO or FFP (i.e.,
extreme lipemia).
Inspection of Donor BloodInspection of Donor Blood
 Segment closest toSegment closest to
unit is hemolyzed.unit is hemolyzed.
 May indicate bacterialMay indicate bacterial
contaminationcontamination
Donor Blood Inspection and Disposition
 If a unit's appearance looks questionable do the
following:
– Quarantine unit until disposition is decided.
– Gently mix, allow to settle and observe appearance.
 If bacterial contamination is suspected the unit should be
cultured and a gram stain performed.
 Positive blood cultures usually indicative of:
– Inadequate donor arm preparation
– Improper pooling technique
– Health of donor - bacteremia in donor
 If one component is contaminated, other components
prepared from the same donor unit may be
contaminated.
Inspection of Donor BloodInspection of Donor Blood
 Reissuing blood cannot be done unless the following
criteria is met:
– Container closure must not have been penetrated or entered in
any manner.
– Most facilities set 30" time limit for accepting units back, warming
above 6-10C even with subsequent cooling increases RBC
metabolism producing hemolysis and permitting bacterial
growth.
– Blood must have been kept at the appropriate temperature.
– One sealed segment must remain attached to container.
– Records must indicate that blood has been reissued and
inspected prior to reissue.
Transportation of Blood and Blood
Components
 WB and RBC
– Sturdy well insulated cardboard and/or
styrofoam container, wet ice in ziplock bag to
cool, temperature must be monitored.
– Mobile collection units should transport blood
ASAP and leave at RT if platelets are to be
made.
– In-house transport place in cooler with wet
ice and thermometer, monitor temperature
every 30 minutes.
Safe-T-Vue Temperature MonitorSafe-T-Vue Temperature Monitor
Transportation of Blood and Blood
Components
 Frozen components
– Temperature must be maintained at or below required
storage temperature.
– Use dry ice in well insulated container.
 Platelets and granulocytes
– Maintain at 20-24 C.
– Transport in well insulated containers without ice.
 Commercial coolers available to maintain at 20-
24C.
Transportation of Blood and Blood
Components
 Handling donor units
– Should not remain at RT unnecessarily, when
blood is issued it should be transfused as
soon as possible.
– When numerous units are removed from
fridge, remove fluid filled container with a
thermometer at same time as blood, when
temperature reaches 6 C return to fridge.
Records
 Must be made concurrently with each step
of component preparation, being as
detailed as possible for clear
understanding.
 Must be legible and indelible.
 Must include dates of various steps and
person responsible.
Bb unit2 bloodcomponentsspring2010
EXAM 1 ONLINE

More Related Content

PPTX
Quality and blood bank
PPTX
Blood bank
PPTX
Compatibility testing
PPTX
Pre tranfusion test
PPTX
quality control in blood banking
PPTX
Anticoagulants and blood preservatives
PDF
Introduction to Apheresis (Dr. Nashwa Elsayed)
PDF
Blood componenet preservation and storage
Quality and blood bank
Blood bank
Compatibility testing
Pre tranfusion test
quality control in blood banking
Anticoagulants and blood preservatives
Introduction to Apheresis (Dr. Nashwa Elsayed)
Blood componenet preservation and storage

What's hot (20)

PPT
‫Pretransfusion testing final- ab screening - NAGLAA MAKRAM
PPT
Pre transfusion testing, dr. rafiq
DOCX
DMLT Biochemistry Model question papers Karnataka 2019-2020
PPTX
Blood components
PPT
Ab identificationreneewilkins
PPT
Recent advances in blood banking
PPT
PPTX
QUALITY CONTROL IN BLOOD BANKING.pptx
PPTX
Hepatitis b(surface antigen) strip method
PPTX
Electronic crossmatch
PPTX
Compatibility testing
PPTX
Hematopoiesis: Origin and development of blood cells
PDF
Forward and reverse grouping by Negash Alamin
PDF
PPT
Morphology of white blood cells
PPTX
Transfusion Medicine- An Introduction and Basics of Screening Blood Donors
PDF
Introduction to blood transfusion
PPTX
Blood transfusion services qc
PPTX
Discrepancies
PPT
Blood component new
‫Pretransfusion testing final- ab screening - NAGLAA MAKRAM
Pre transfusion testing, dr. rafiq
DMLT Biochemistry Model question papers Karnataka 2019-2020
Blood components
Ab identificationreneewilkins
Recent advances in blood banking
QUALITY CONTROL IN BLOOD BANKING.pptx
Hepatitis b(surface antigen) strip method
Electronic crossmatch
Compatibility testing
Hematopoiesis: Origin and development of blood cells
Forward and reverse grouping by Negash Alamin
Morphology of white blood cells
Transfusion Medicine- An Introduction and Basics of Screening Blood Donors
Introduction to blood transfusion
Blood transfusion services qc
Discrepancies
Blood component new
Ad

Similar to Bb unit2 bloodcomponentsspring2010 (20)

PPT
Blood Tranfusion Therapy
PPT
Blood transfusion
PPTX
PREPARATION, STORAGE & USAGE OF BLOOD COMPONENT edit.pptx
PPT
Blood transfusion, Nutrition and water & electrolyte balance
PPTX
Blood transfusion part 1
PPT
Blood components preparation and therapeutic uses final
PPT
Blood components preparation and therapeutic uses final
PDF
Component prep and therapy
PDF
Updates on blood transfusion
PPTX
blood banking ..Preparation of blood components and their therapeutic uses
PDF
Blood components
PDF
Blood components
PPTX
Blood component therapy part I
PPTX
Blood component therapy
PPTX
Blood component storage and screening.pptx
PPTX
Blood component therapy
PPTX
blood seminar by anaesthesia contains blood transfusion
PPTX
Blood component therapy in newborn and children jyoti
PPTX
Blood products:Collection, Processing and Storage of whole human blood, dried...
PPT
Massive Transfusion and Coagulopathy.ppt
Blood Tranfusion Therapy
Blood transfusion
PREPARATION, STORAGE & USAGE OF BLOOD COMPONENT edit.pptx
Blood transfusion, Nutrition and water & electrolyte balance
Blood transfusion part 1
Blood components preparation and therapeutic uses final
Blood components preparation and therapeutic uses final
Component prep and therapy
Updates on blood transfusion
blood banking ..Preparation of blood components and their therapeutic uses
Blood components
Blood components
Blood component therapy part I
Blood component therapy
Blood component storage and screening.pptx
Blood component therapy
blood seminar by anaesthesia contains blood transfusion
Blood component therapy in newborn and children jyoti
Blood products:Collection, Processing and Storage of whole human blood, dried...
Massive Transfusion and Coagulopathy.ppt
Ad

Bb unit2 bloodcomponentsspring2010

  • 1. II. Blood and BloodII. Blood and Blood ComponentsComponents Terry Kotrla, MS, MT(ASCP)BBTerry Kotrla, MS, MT(ASCP)BB Spring 2010Spring 2010
  • 2. Goals Of Blood CollectionGoals Of Blood Collection  Maintain viability and functionMaintain viability and function  Prevent physical changesPrevent physical changes  Minimize bacterial contaminationMinimize bacterial contamination
  • 3. Anticoagulants Preservative Solutions  Anticoagulants prevent blood clottingAnticoagulants prevent blood clotting  Preservatives provide nutrients for cellsPreservatives provide nutrients for cells  HeparinHeparin – Rarely if ever used anymoreRarely if ever used anymore – Anticoagulant ONLYAnticoagulant ONLY – Transfuse within 48 hours, preferably 8Transfuse within 48 hours, preferably 8
  • 4. AnticoagulantsAnticoagulants CPDCPD CPD-A1CPD-A1 Storage timeStorage time 21 days21 days 35 days35 days TemperatureTemperature 1-6 C1-6 C 1-6 C1-6 C Slows glycolytic activitySlows glycolytic activity AdenineAdenine NoneNone Substrate for ATP synthesisSubstrate for ATP synthesis VolumeVolume 450 +/- 10%450 +/- 10% DextroseDextrose Supports ATP generation by glycolyticSupports ATP generation by glycolytic pathwaypathway CitrateCitrate Prevents coagulation by binding calciumPrevents coagulation by binding calcium
  • 5. Additive SolutionAdditive Solution  Primary bag with satellite bags attached.Primary bag with satellite bags attached.  One bag has additive solution (AS)One bag has additive solution (AS)  Unit drawn into CPD anticoagulantUnit drawn into CPD anticoagulant
  • 6. Additive SolutionAdditive Solution  Remove platelet rich plasma within 72 hoursRemove platelet rich plasma within 72 hours  Add additive solution to RBCs, ADSOL, whichAdd additive solution to RBCs, ADSOL, which consists of:consists of: – SalineSaline – AdenineAdenine – GlucoseGlucose – MannitolMannitol  Extends storage to 42 daysExtends storage to 42 days  Final hematocrit approximately 66%Final hematocrit approximately 66%
  • 7. Changes Occur During StorageChanges Occur During Storage  Shelf life = expiration dateShelf life = expiration date – At end of expiration must have 75% recoveryAt end of expiration must have 75% recovery – At least 75% of transfused cells remain inAt least 75% of transfused cells remain in circulation 24 hours AFTER transfusioncirculation 24 hours AFTER transfusion
  • 8. Storage LesionStorage Lesion  Biochemical changes which occur at 1-6CBiochemical changes which occur at 1-6C  Affects oxygen dissociation curve, increasedAffects oxygen dissociation curve, increased affinity of hemoglobin for oxygen.affinity of hemoglobin for oxygen. – Low 2,3-DPG, increased OLow 2,3-DPG, increased O22 affinity, less Oaffinity, less O22 released.released. – pH drops causes 2,3-DPG levels to fallpH drops causes 2,3-DPG levels to fall – Once transfused RBCs regenerate ATP and 2,3-DPGOnce transfused RBCs regenerate ATP and 2,3-DPG  Few functional platelets presentFew functional platelets present  Viable (living) RBCs decreaseViable (living) RBCs decrease
  • 9. Plasma hemoglobin Plasma K+ Viable cells pH ATP 2,3-DPG Plasma Na+ Helps release oxygen from hemoglobin (once transfused, ATP & 2,3- DPG return to normal) K+Na+
  • 10. Storage LesionStorage Lesion  Significant for infants and massiveSignificant for infants and massive transfusion.transfusion.  Other biochemical changesOther biochemical changes – ATP decreasesATP decreases – Potassium increasesPotassium increases – Sodium decreasesSodium decreases – Plasma hemoglobin increasesPlasma hemoglobin increases
  • 11. Preparation of ComponentsPreparation of Components  Collect unit within 15 minutes to preventCollect unit within 15 minutes to prevent activation of coagulation systemactivation of coagulation system  Draw into closed system – primary bag withDraw into closed system – primary bag with satellite bags with hermetic seal between.satellite bags with hermetic seal between.  If hermetic seal broken transfuse within 24 hoursIf hermetic seal broken transfuse within 24 hours if stored at 1-4C, 4 hours if stored at 20-24Cif stored at 1-4C, 4 hours if stored at 20-24C
  • 12. Preparation of ComponentsPreparation of Components  Centrifuge – light spin, platelets suspendedCentrifuge – light spin, platelets suspended  Remove platelet rich plasma (PRP)Remove platelet rich plasma (PRP)  Centrifuge PRP heavy spinCentrifuge PRP heavy spin  Remove platelet poor plasmaRemove platelet poor plasma  Freeze plasma solid within 8 hoursFreeze plasma solid within 8 hours  Thaw plasma at 1-4C – precipitate formsThaw plasma at 1-4C – precipitate forms  Centrifuge, express plasma leavingCentrifuge, express plasma leaving cryoprecipitate. Store both at -18Ccryoprecipitate. Store both at -18C  RBCs – CPD – 21 days, ADSOL – 42 days – 1-RBCs – CPD – 21 days, ADSOL – 42 days – 1- 6C6C
  • 14. Preparation of ComponentsPreparation of Components  Summary – One unit of whole blood canSummary – One unit of whole blood can produce:produce: – Packed RBCsPacked RBCs – Fresh frozen plasma (FFP)Fresh frozen plasma (FFP) – Cryoprecipitate (CRYO)Cryoprecipitate (CRYO) – Single donor plasma (SDP) – cyro removedSingle donor plasma (SDP) – cyro removed – Platelets – terms PC (platelet concentrate) ORPlatelets – terms PC (platelet concentrate) OR RD PC (random donor platelet concentrate)RD PC (random donor platelet concentrate)
  • 15. Preparation of ComponentsPreparation of Components  Sterile docking device joins tubingSterile docking device joins tubing – Used to add satellite bags to maintain originalUsed to add satellite bags to maintain original expiration of componentexpiration of component – May be used to pool componentsMay be used to pool components
  • 16. Blood Component General InformationBlood Component General Information  Blood separated into components toBlood separated into components to specifically treat patients with productspecifically treat patients with product neededneeded  Advantages of component separationAdvantages of component separation – Allow optimum survival of each componentAllow optimum survival of each component – Transfuse only component neededTransfuse only component needed
  • 17. Blood Component General InformationBlood Component General Information  Transfusion practiceTransfusion practice – Transfusion requires doctor’s prescriptionTransfusion requires doctor’s prescription – All components MUST be administeredAll components MUST be administered through a filterthrough a filter – Infuse quickly, within 4 hoursInfuse quickly, within 4 hours – D (Rh) neg require D neg cellular productsD (Rh) neg require D neg cellular products – ABO identical preferred, ABO compatible OKABO identical preferred, ABO compatible OK – ““Universal donor” – RBCs group O, plasmaUniversal donor” – RBCs group O, plasma ABAB
  • 18. Blood Component General InformationBlood Component General Information  Fresh Whole BloodFresh Whole Blood – Blood not usually available until 12-24 hoursBlood not usually available until 12-24 hours – CandidatesCandidates  Newborns needing exchange transfusionNewborns needing exchange transfusion  Patients requiring leukoreduced productsPatients requiring leukoreduced products
  • 19. Blood Component General InformationBlood Component General Information  Summary of storage temperatures:Summary of storage temperatures: – Liquid RBCs 1-6CLiquid RBCs 1-6C – Platelets, Cryo (thawed) and granulocytes 20-Platelets, Cryo (thawed) and granulocytes 20- 24C (room temperature)24C (room temperature) – ANY frozen plasma product ≤ -18CANY frozen plasma product ≤ -18C – ANY liquid plasma product EXCEPT Cryo 1-ANY liquid plasma product EXCEPT Cryo 1- 6C6C
  • 20. Blood ComponentsBlood Components  CellularCellular – Red blood cell productsRed blood cell products – PlateletsPlatelets – GranulocytesGranulocytes  PlasmaPlasma – FFPFFP – CryoprecipitateCryoprecipitate
  • 21. Products With Red CellsProducts With Red Cells
  • 22. Whole BloodWhole Blood  Clinical indications for use of WB are extremely limited.  Used for massive transfusion to correct acute hypovolemia such as in trauma and shock, exchange transfusion.  RARELY used today, platelets non-functional, labile coagulation factors gone.  Must be ABO identical.
  • 23. Changes in Stored BloodChanges in Stored Blood
  • 24. Red Blood Cells, PackedRed Blood Cells, Packed (PRBC)(PRBC)  Used to treat symptomatic anemia and routine blood loss during surgery  Hematocrit is approximately 80% for non- additive (CPD), 60% for additive (ADSOL).  Allow WB to sediment or centrifuge WB, remove supernatant plasma.
  • 25. Leukocyte Reduced Red Cells (LR-Leukocyte Reduced Red Cells (LR- RBC)RBC)  Leukocytes can induce adverse affects during transfusion, primarily febrile, non-hemolytic reactions.  Reactions to cytokines produced by leukocytes in transfused units.  Other explanations to reactions include: immunization of recipient to transfused HLA or granulocyte antigens, micro aggregates and fragmentation of granulocytes.  Historically, indicated only for patients who had 2 or more febrile transfusion reactions, now a commonly ordered, popular component.  “CMV” safe blood, since CMV lives in WBCs.  Most blood centers now leukoreduce blood immediately after collection.  Bed side filters are available to leukoreduce products during transfusion.
  • 27. Washed Red Blood Cells (W- RBCs)  Washing removes plasma proteins, platelets, WBCs and micro aggregates which may cause febrile or urticarial reactions.  Patient requiring this product is the IgA deficient patient with anti-IgA antibodies.  Prepared by using a machine which washes the cells 3 times with saline to remove and WBCs.  Two types of labels: – Washed RBCs - do not need to QC for WBCs. – Leukocyte Poor WRBCs, QC must be done to guarantee removal of 85% of WBCs. No longer considered effective method for leukoreduction.  e. Expires 24 hours after unit is entered.
  • 28. Cell Washer to Prepare WashedCell Washer to Prepare Washed CellsCells
  • 30. Red Blood Cells Frozen; Red Blood Cells Deglycerolized (D-RBC)  Blood is frozen to preserve: rare types, for autologous transfusion, stock piling blood for military mobilization and/or civilian natural disasters.  Blood is drawn into an anticoagulant preservative. – Plasma is removed and glycerol is added. – After equilibration unit is centrifuged to remove excess glycerol and frozen.  Expiration – If frozen, 10 years. – After deglycerolization, 24 hours.  Storage temperature – high glycerol -65 C. – low glycerol -120 C, liquid nitrogen.
  • 31. Red Blood Cells Frozen; Red Blood Cells Deglycerolized (D-RBC)  Thaw unit at 37C, thawed RBCs will have high concentration of glycerol.  A solution of glycerol of lesser concentration of the original glycerol is added.  This causes glycerol to come out of the red blood cells slowly to prevent hemolysis of the RBCs.  After a period of equilibration the unit is spun, the solution is removed and a solution with a lower glycerol concentration is added.  This procedure is repeated until all glycerol is removed, more steps are required for the high glycerol stored units.  The unit is then washed.
  • 32. Rejuvenated Red Blood Cells  A special solution is added to expired RBCs up to 3 days after expiration to restore 2,3-DPG and ATP levels to prestorage values.  Rejuvenated RBCs regain normal characteristics of oxygen transport and delivery and improved post transfusion survival.  Expiration is 24 hours or, if frozen, 10 years
  • 34. Platelets (PLTS), Platelet Concentrate (PC) or Random Donor Platelet Concentrate (RD-PC)  Used to prevent spontaneous bleeding or stop established bleeding in thrombocytopenic patients.  Prepared from a single unit of whole blood.  Due to storage at RT it is the most likely component to be contaminated with bacteria.  Therapeutic dose for adults is 6 to 10 units.  Some patients become "refractory" to platelet therapy.  Expiration is 5 days as a single unit, 4 hours if pooled.  Store at 20-24 C (RT) with constant agitation.  D negative patients should be transfused with D negative platelets due to the presence of a small number of RBCs.
  • 35. Preparation of plateletPreparation of platelet concentrateconcentrate RBCs PRP Plasma Platelet concentrate
  • 36. Platelets (PLTS), Platelet Concentrate (PC) or Random Donor Platelet Concentrate (RD-PC)  One bag from ONE donorOne bag from ONE donor  Need 6-10 for therapeutic doseNeed 6-10 for therapeutic dose
  • 37. Pooling PlateletsPooling Platelets  6-10 units transferred into one bag6-10 units transferred into one bag  Expiration = 4 hoursExpiration = 4 hours
  • 38. Platelets Pheresis, Apheresis Platelet Concentrate, Single Donor Platelet Concentrate (SD-PC)  Used to decrease donor exposure, obtain HLA matched platelets for patients who are refractory to RD-PC or prevent platelet refractoriness from occurring.  Prepared by hemapheresis, stored in two connected bags to maintain viability.  One pheresed unit is equivalent to 6-8 RD-PC.  Store at 20-24 C (RT) with agitation for 5 days, after combining, 24 hours  D negative patients should be transfused with D negative platelets due to the presence of a small number of RBCs
  • 41. Platelets Pheresis  One bag (unit) fromOne bag (unit) from one donorone donor  One unit is aOne unit is a therapeutic dosetherapeutic dose  VolumeVolume approximately 250approximately 250 ccsccs
  • 43. Granulocytes  Primary use is for patients with neutropenia who have gram negative infections documented by culture, but are unresponsive to antibiotics.  Therapeutic efficacy and indications for granulocyte transfusions are not well defined.  Better antimicrobial agents and use of granulocyte and macrophage colony stimulating factors best for adults, best success with this component has been with babies  Daily transfusions are necessary.  Prepared by hemapheresis.  Expiration time is 24 hours but best to infuse ASAP.  Store at 20-24 C.
  • 45. Fresh Frozen Plasma –Fresh Frozen Plasma – Volume 200-250ccVolume 200-250cc
  • 46. Fresh Frozen Plasma (FFP)  Used to replace labile and non-labile coagulation factors in massively bleeding patients OR treat bleeding associated with clotting factor deficiencies when factor concentrate is not available.  Must be frozen within 8 hours of collection.  Expiration – frozen - 1 year stored at <-18 C. – frozen - 7 years stored at <-65 C.thawed - 24 hours
  • 47. Fresh Frozen Plasma (FFP)  Storage temperature – frozen -18 C, preferably -30 C or lower – thawed - 1-6 C  Thawed in 30-37C water bath or FDA approved microwave  Must have mechanism to detect units which have thawed and refrozen due to improper storage.  Must be ABO compatible
  • 48. Plasma, Liquid Plasma, Recovered Plasma and Source Plasma  Used to treat patients with stable clotting factor deficiencies for which no concentrate is available or for patients undergoing therapeutic plasmapheresis.  Prepared by separating the plasma from the RBCs on or before the 5th day after expiration of the whole blood.  Once separated can: – Freeze, store at -18 C for 5 years – If not frozen, called liquid plasma, store at 1-6 C for up to 5 days after expiration of WB.  Once FFP is one year old can redesignate as Plasma, expiration is 5 years.
  • 49. Pooled Plasma/Solvent Detergent Treated  Most recently licensed product.  Prepared from pools of no more than 2500 units of ABO specific plasma frozen to preserve labile coagulation factors.  Treated with chemicals to inactivate lipid-enveloped viruses.  Contains labile and non-labile coagulation factors but lacks largest Von Willebrand’s factor multimers.  Used same as FFP.Safety concerns – Decreases disease transmission for diseases tested for. – Doesn’t inactivate viruses with non-lipid envelopes: parvo virus B19, hepatitis A, and unrecognized pathogens
  • 50. Cryoprecipitate (CRYO), Factor VIII or Anti-Hemophilic Factor (AHF)  Cold insoluble portion of plasma that precipitates when FFP is thawed at 1-6C.  Cryoprecipitate contains high levels of Factor VIII and Fibrinogen, used for treatment of hemophiliacs and Von Willebrands when concentrates are not available.  Used most commonly for patients with DIC or low fibrinogen levels.  A therapeutic dose for an adult is 6 to 10 units.  Can be prepared from WB which is then designated as "Whole Blood Cryoprecipitate Removed" or from FFP – Plasma is frozen. – Plasma is then thawed at 1-6 C, a precipitate forms. – Plasma is centrifuged, cryoprecipitate will go to bottom. – Remove plasma, freeze within 1 hour of preparation
  • 51. FFP Frozen within 8 hours Thawed FFP Cryoprecipitate (VIII, vW) Plasma cryoprecipitate, reduced (TTP, FII, V, Vii, IX, X, XI) Thaw at 30-37°C Store at RT 4 hrs Refrozen with 24 hrs of separation Store at ≤18°C 1 yr 5 day expiration at 1-6°C
  • 52. Cryoprecipitate (CRYO), Factor VIII or Anti-Hemophilic Factor (AHF)  Storage Temperature – Frozen -18 C or lower – Thawed - room temperature  Expiration: – Frozen 1 year – Thawed 6 hours – Pooled 4 hours  Best to be ABO compatible but not important due to small volume
  • 53. Cryoprecipitate – volume 15ccsCryoprecipitate – volume 15ccs
  • 54. Irradiation of Blood Components
  • 55. Irradiation of Blood Components  Cellular blood components are irradiated to destroy viable T- lymphocytes which may cause Graft Versus Host Disease (GVHD).  GVHD is a disease that results when immunocompetent, viable lymphocytes in donor blood engraft in an immunocompromised host, recognize the patient tissues as foreign and produce antibodies against patient tissues, primarily skin, liver and GI tract. The resulting disease has serious consequences including death.  GVHD may be chronic or acute
  • 56. Irradiation of Blood Components  Patients at greatest risk are: – severely immunosuppressed, – immunocompromised, – receive blood donated by relatives, or – fetuses receiving intrauterine transfusions  Irradiation inactivates lymphocytes, leaving platelets, RBCs and granulocytes relatively undamaged.  Must be labeled "irradiated".  Expiration date of Red Blood Cell donor unit changes to 28 days.  May be transfused to "normal" patients if not used by intended recipient.
  • 57. Irradiation of Blood Components
  • 58. Donor Blood Inspection and Disposition  It is required that donor units be inspected periodically during storage and prior to issuing to patient.  The following may indicate an unacceptable unit: – Red cell mass looks purple or clots are visible. – Zone of hemolysis observed just above RBC mass, look for hemolysis in sprigs, especially those closest to the unit. – Plasma or supernatant plasma appears murky, purple, brown or red. – A greenish hue need not cause a unit to be rejected. – Inspect platelets for aggregates.  Inspect FFP and CRYO for signs of thawing, evidence of cracks in bag, or unusual turbidity in CRYO or FFP (i.e., extreme lipemia).
  • 59. Inspection of Donor BloodInspection of Donor Blood  Segment closest toSegment closest to unit is hemolyzed.unit is hemolyzed.  May indicate bacterialMay indicate bacterial contaminationcontamination
  • 60. Donor Blood Inspection and Disposition  If a unit's appearance looks questionable do the following: – Quarantine unit until disposition is decided. – Gently mix, allow to settle and observe appearance.  If bacterial contamination is suspected the unit should be cultured and a gram stain performed.  Positive blood cultures usually indicative of: – Inadequate donor arm preparation – Improper pooling technique – Health of donor - bacteremia in donor  If one component is contaminated, other components prepared from the same donor unit may be contaminated.
  • 61. Inspection of Donor BloodInspection of Donor Blood  Reissuing blood cannot be done unless the following criteria is met: – Container closure must not have been penetrated or entered in any manner. – Most facilities set 30" time limit for accepting units back, warming above 6-10C even with subsequent cooling increases RBC metabolism producing hemolysis and permitting bacterial growth. – Blood must have been kept at the appropriate temperature. – One sealed segment must remain attached to container. – Records must indicate that blood has been reissued and inspected prior to reissue.
  • 62. Transportation of Blood and Blood Components  WB and RBC – Sturdy well insulated cardboard and/or styrofoam container, wet ice in ziplock bag to cool, temperature must be monitored. – Mobile collection units should transport blood ASAP and leave at RT if platelets are to be made. – In-house transport place in cooler with wet ice and thermometer, monitor temperature every 30 minutes.
  • 64. Transportation of Blood and Blood Components  Frozen components – Temperature must be maintained at or below required storage temperature. – Use dry ice in well insulated container.  Platelets and granulocytes – Maintain at 20-24 C. – Transport in well insulated containers without ice.  Commercial coolers available to maintain at 20- 24C.
  • 65. Transportation of Blood and Blood Components  Handling donor units – Should not remain at RT unnecessarily, when blood is issued it should be transfused as soon as possible. – When numerous units are removed from fridge, remove fluid filled container with a thermometer at same time as blood, when temperature reaches 6 C return to fridge.
  • 66. Records  Must be made concurrently with each step of component preparation, being as detailed as possible for clear understanding.  Must be legible and indelible.  Must include dates of various steps and person responsible.

Editor's Notes

  • #10: pH maintained by the phosphate